|1.||Williams, Jon I: 7 articles (01/2014 - 09/2009)|
|2.||Gomes, Paul J: 6 articles (01/2014 - 09/2009)|
|3.||McNamara, Timothy R: 6 articles (05/2013 - 09/2009)|
|4.||Gow, James A: 6 articles (05/2013 - 09/2009)|
|5.||Torkildsen, Gail L: 4 articles (05/2012 - 09/2009)|
|6.||Abelson, Mark B: 4 articles (08/2011 - 09/2009)|
|7.||Bepotastine Besilate Ophthalmic Solutions Clinical Study Group: 3 articles (07/2010 - 09/2009)|
|8.||Bergmann, Mark T: 2 articles (01/2014 - 07/2010)|
|9.||Bepotastine Besilate Ophthalmic Solutions Study Group: 2 articles (05/2012 - 08/2011)|
|10.||Susuta, Yutaka: 1 article (11/2015)|
|1.||Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
05/01/2013 - "Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial."
07/01/2010 - "To evaluate the safety and efficacy of 1.5% bepotastine besilate ophthalmic solution in alleviating nonocular symptoms induced by a conjunctival allergen challenge (CAC), a clinical model of allergic conjunctivitis. "
01/01/2014 - "Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%."
08/01/2011 - "Subjects with a history of allergic conjunctivitis were assigned to receive placebo or bepotastine besilate ophthalmic solution 1.0% or 1.5% in a single-center, randomized, placebo-controlled clinical trial. "
08/01/2011 - "Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis."
01/01/2012 - "At study end, 63.3% and 66.7% of patients preferred bepotastine besilate 1.5% for all-day relief of ocular itching and all-day relief of itchy/runny nose, respectively. "
08/01/2011 - "Bepotastine besilate ophthalmic solution 1.5% produced predefined clinically meaningful reduction in CAC-induced ocular itching and tearing in a single-site trial and was more effective than bepotastine besilate ophthalmic solution 1.0% and placebo for reducing ocular itching in a CAC test 16 h after dosing."
12/01/2013 - "Bepotastine besilate for the treatment of pruritus."
08/01/2011 - "Bepotastine besilate ophthalmic solution 1.0% also achieved statistical significance in comparison to placebo for reducing ocular itching at all time points 16 h after dosing. "
08/01/2011 - "Bepotastine besilate ophthalmic solution 1.5% demonstrated clinical effectiveness and statistical significance in comparison to placebo for the reduction in CAC-induced ocular itching 16 h after drug administration. "
|3.||Perennial Allergic Rhinitis
11/01/2015 - "Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis."
11/01/2015 - "Although second-generation antihistamines, such as bepotastine besilate, are recommended as a first-line treatment option for adult perennial allergic rhinitis (PAR), few non-sedating second-generation antihistamines are safe for children. "
07/01/2010 - "Statistically significant reductions in conjunctival hyperemia (P < or = .0125) were observed for bepotastine besilate ophthalmic formulations only at the onset of action CAC test. "
09/01/2009 - "Statistically significant reductions in conjunctival hyperemia were achieved with both bepotastine besilate concentrations. "
09/01/2009 - "The aim of this study was to assess the effects of bepotastine besilate ophthalmic solution 1.0% and 1.5% for the treatment of ocular itching and conjunctival hyperemia in a conjunctival allergen challenge (CAC) model in adults and children. "
09/01/2009 - "Patients received bepotastine besilate ophthalmic solution 1.0%, bepotastine besilate ophthalmic solution 1.5%, or placebo, 1 drop on each eye on days 14 +/- 3 and 28 +/- 3. The primary efficacy end points, patient-assessed ocular itching (at 3, 5, and 7 minutes) and investigator-assessed conjunctival hyperemia (at 7, 15, and 20 minutes), were determined after CAC according to standardized 5-point scales (0 = none to 4 = severe). "
07/01/2010 - "Reductions in conjunctival hyperemia after a CAC, although statistically significant for bepotastine besilate ophthalmic solutions 1.0% and 1.5% compared with placebo when assessed at 15 minutes after dosing, were modest."
|1.||Non-Sedating Histamine H1 Antagonists (Histamine H1 Antagonists, Non Sedating)
|3.||Ophthalmic Solutions (Eye Drops)
|4.||Histamine (Histamine Dihydrochloride)